Table 2. Immunosuppressive agents used in analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States.
| Agent |
|---|
| Chemotherapeutic |
| Aldesleukin |
| Alemtuzumab |
| Altretamine |
| Amifostine |
| Arsenic trioxide |
| Asparaginase |
| Azacitidine |
| Bendamustine hydrochloride |
| Bevacizumab |
| Bexarotene |
| Bortezomib |
| Brentuximab vedotin |
| Busulfan |
| Cabazitaxel |
| Capecitabine |
| Carboplatin |
| Carfilzomib |
| Carmustine |
| Cetuximab |
| Chlorambucil |
| Cisplatin |
| Cladribine |
| Clofarabine |
| Cyclophosphamide |
| Dacarbazine |
| Dactinomycin |
| Dasatinib |
| Daunorubicin citrate liposome |
| Decitabine |
| Denileukin diftitox |
| Docetaxel |
| Etoposide |
| Everolimus |
| Floxuridine |
| Fluorouracil |
| Gefitinib |
| Ifosfamide |
| Ipilimumab |
| Ixabepilone |
| Lomustine |
| Melphalan |
| Mercaptopurine |
| Mesna |
| Methotrexate |
| Mitomycin |
| Mitotane |
| Nelarabine |
| Ofatumumab |
| Oxaliplatin |
| Paclitaxel |
| Panitumumab |
| Pegaspargase |
| Pemetrexed |
| Pentostatin |
| Pertuzumab |
| Plicamycin |
| Pralatrexate |
| Rituximab |
| Romidepsin |
| Streptozocin |
| Temozolomide |
| Teniposide |
| Thioguanine |
| Thiotepa |
| Trastuzumab |
| Tretinoin |
| Vorinostat |
| Immune-modulating |
| Abatacept |
| Adalimumab |
| Alefacept |
| Anakinra |
| Auranofin |
| Aurothioglucose |
| Azathioprine |
| Basiliximab |
| Belatacept |
| Belimumab |
| Certolizumab pegol |
| Cyclosporine |
| Daclizumab |
| Denosumab |
| Eculizumab |
| Efalizumab |
| Etanercept |
| Gold sodium thiomalate |
| Golimumab |
| Infliximab |
| Interferon alfacon-1 |
| Leflunomide |
| Lenalidomide |
| Mycophenolate mofetil |
| Natalizumab |
| Palifermin |
| Palivizumab |
| Pegademase bovine |
| Pimecrolimus |
| Sirolimus |
| Tacrolimus |
| Thalidomide |
| Tocilizumab |
| Ustekinumab |
| Systemic corticosteroids |
| Dexamethasone |
| Methylprednisolone |
| Prednisolone |
| Prednisone |